Evaluation of Therapeutic Response to Endocrine Therapy for Prostate Cancer by MRI Diffusion-weighted Imaging Based on PI-RADSv2.1
Objective To investigate the value of MRI diffusion-weighted imaging (DWI) technique in endocrine therapy for prostate cancer (PCa) based on PI-RADSv2.1. Methods A retrospective analysis of 57 patients with pathologically confirmed PCa was conducted. All patients underwent multi-parametric MRI (mpMR...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2023-07-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1396 |
| _version_ | 1797737713667932160 |
|---|---|
| author | LI Basen LIU Liangjin RUAN Yajun TAN Fangqin LI Qin HAN Yunfeng |
| author_facet | LI Basen LIU Liangjin RUAN Yajun TAN Fangqin LI Qin HAN Yunfeng |
| author_sort | LI Basen |
| collection | DOAJ |
| description | Objective To investigate the value of MRI diffusion-weighted imaging (DWI) technique in endocrine therapy for prostate cancer (PCa) based on PI-RADSv2.1. Methods A retrospective analysis of 57 patients with pathologically confirmed PCa was conducted. All patients underwent multi-parametric MRI (mpMRI) according to PI-RADS v2.1 technical specifications before biopsy and six months after endocrine therapy. The apparent diffusion coefficient (ADC) values were measured in cancer and non-cancer areas before biopsy and six months after endocrine therapy. Patients were grouped based on the mRECIST criteria and PSA level into responders (n=45) and non-responders (n=12). ROC curves were obtained to assess the correlation between changes in ADC values and PSA values before and after endocrine therapy. Results In the responder group, the ADC value of the cancer areas was increased significantly after endocrine therapy (P<0.001). No statistically significant difference of the ADC value of the cancer areas was found in the non-responder group before and six months after endocrine therapy (P=0.714). The ADC change of responders and non-responder groups were (0.411±0.178)×10-3 mm2/s and (-0.014±0.125)×10-3 mm2/s, respectively (P<0.001); the ADC ratio were (60.603±30.201)% and (-1.096±13.175)%, respectively (P<0.001). The cutoff value of the ADC change was 0.165 (AUC=0.974; sensitivity, 88.89%; specificity, 100.00%; PPV, 100.00%; NPV, 70.59%). The cutoff value of ADC ratio was 16.827% (AUC=0.980; sensitivity, 91.11%; specificity, 100.00%; PPV, 100.00%; NPV, 75.00%). The ADC values were negatively correlated with serum PSA before and after endocrine therapy. Conclusion The ADC change and ADC ratio may be facilitated to monitor the efficacy of endocrine therapy for PCa. The ADC values were negatively correlated with serum PSA. |
| first_indexed | 2024-03-12T13:32:27Z |
| format | Article |
| id | doaj.art-7257a2209c924a3aacc7f410c2b4ce8d |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-03-12T13:32:27Z |
| publishDate | 2023-07-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-7257a2209c924a3aacc7f410c2b4ce8d2023-08-24T06:55:31ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782023-07-0150769469910.3971/j.issn.1000-8578.2023.22.13968578.2023.22.1396Evaluation of Therapeutic Response to Endocrine Therapy for Prostate Cancer by MRI Diffusion-weighted Imaging Based on PI-RADSv2.1LI Basen0LIU Liangjin1RUAN Yajun2TAN Fangqin3LI Qin4HAN Yunfeng5Department of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, ChinaDepartment of Radiology, Hubei No. 3 People's Hospital of Jianghan University, Wuhan 430033, ChinaDepartment of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, ChinaDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, ChinaDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, ChinaDepartment of Nuclear Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, ChinaObjective To investigate the value of MRI diffusion-weighted imaging (DWI) technique in endocrine therapy for prostate cancer (PCa) based on PI-RADSv2.1. Methods A retrospective analysis of 57 patients with pathologically confirmed PCa was conducted. All patients underwent multi-parametric MRI (mpMRI) according to PI-RADS v2.1 technical specifications before biopsy and six months after endocrine therapy. The apparent diffusion coefficient (ADC) values were measured in cancer and non-cancer areas before biopsy and six months after endocrine therapy. Patients were grouped based on the mRECIST criteria and PSA level into responders (n=45) and non-responders (n=12). ROC curves were obtained to assess the correlation between changes in ADC values and PSA values before and after endocrine therapy. Results In the responder group, the ADC value of the cancer areas was increased significantly after endocrine therapy (P<0.001). No statistically significant difference of the ADC value of the cancer areas was found in the non-responder group before and six months after endocrine therapy (P=0.714). The ADC change of responders and non-responder groups were (0.411±0.178)×10-3 mm2/s and (-0.014±0.125)×10-3 mm2/s, respectively (P<0.001); the ADC ratio were (60.603±30.201)% and (-1.096±13.175)%, respectively (P<0.001). The cutoff value of the ADC change was 0.165 (AUC=0.974; sensitivity, 88.89%; specificity, 100.00%; PPV, 100.00%; NPV, 70.59%). The cutoff value of ADC ratio was 16.827% (AUC=0.980; sensitivity, 91.11%; specificity, 100.00%; PPV, 100.00%; NPV, 75.00%). The ADC values were negatively correlated with serum PSA before and after endocrine therapy. Conclusion The ADC change and ADC ratio may be facilitated to monitor the efficacy of endocrine therapy for PCa. The ADC values were negatively correlated with serum PSA.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1396prostate cancerdiffusion-weighted imagingapparent diffusion coefficientendocrine therapyprostate-specific antigen |
| spellingShingle | LI Basen LIU Liangjin RUAN Yajun TAN Fangqin LI Qin HAN Yunfeng Evaluation of Therapeutic Response to Endocrine Therapy for Prostate Cancer by MRI Diffusion-weighted Imaging Based on PI-RADSv2.1 Zhongliu Fangzhi Yanjiu prostate cancer diffusion-weighted imaging apparent diffusion coefficient endocrine therapy prostate-specific antigen |
| title | Evaluation of Therapeutic Response to Endocrine Therapy for Prostate Cancer by MRI Diffusion-weighted Imaging Based on PI-RADSv2.1 |
| title_full | Evaluation of Therapeutic Response to Endocrine Therapy for Prostate Cancer by MRI Diffusion-weighted Imaging Based on PI-RADSv2.1 |
| title_fullStr | Evaluation of Therapeutic Response to Endocrine Therapy for Prostate Cancer by MRI Diffusion-weighted Imaging Based on PI-RADSv2.1 |
| title_full_unstemmed | Evaluation of Therapeutic Response to Endocrine Therapy for Prostate Cancer by MRI Diffusion-weighted Imaging Based on PI-RADSv2.1 |
| title_short | Evaluation of Therapeutic Response to Endocrine Therapy for Prostate Cancer by MRI Diffusion-weighted Imaging Based on PI-RADSv2.1 |
| title_sort | evaluation of therapeutic response to endocrine therapy for prostate cancer by mri diffusion weighted imaging based on pi radsv2 1 |
| topic | prostate cancer diffusion-weighted imaging apparent diffusion coefficient endocrine therapy prostate-specific antigen |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2023.22.1396 |
| work_keys_str_mv | AT libasen evaluationoftherapeuticresponsetoendocrinetherapyforprostatecancerbymridiffusionweightedimagingbasedonpiradsv21 AT liuliangjin evaluationoftherapeuticresponsetoendocrinetherapyforprostatecancerbymridiffusionweightedimagingbasedonpiradsv21 AT ruanyajun evaluationoftherapeuticresponsetoendocrinetherapyforprostatecancerbymridiffusionweightedimagingbasedonpiradsv21 AT tanfangqin evaluationoftherapeuticresponsetoendocrinetherapyforprostatecancerbymridiffusionweightedimagingbasedonpiradsv21 AT liqin evaluationoftherapeuticresponsetoendocrinetherapyforprostatecancerbymridiffusionweightedimagingbasedonpiradsv21 AT hanyunfeng evaluationoftherapeuticresponsetoendocrinetherapyforprostatecancerbymridiffusionweightedimagingbasedonpiradsv21 |